Financing channel feed – Endpoints News

Financing channel feed

SpyBiotech cashes in on Serum Institute deal, netting $32.5M round for its 'superglue' VLP vaccine tech

5 years ago

Stephen Elledge's Harvard lab takes $17M to birth ImmuneID, a high-throughput antibody startup

5 years ago

GlaxoSmithKline bets another $345M cash on Vir, expanding Covid-19 partnership to flu, RSV and other viruses

5 years ago

Pioneering regenerative med scientist Laura Niklason takes her company public in the latest big SPAC deal. And that gives her a shot at making biotech history

5 years ago

'I’m not trying to rebuild an ego': Neil Woodford appeals to professionals for his comeback biotech fund

5 years ago

Khosla bets big on SPAC boom, raising $1.2 billion for 3 vaguely targeted blank-check companies

5 years ago

A pair of biotechs prepares to hit Nasdaq, as total 2021 IPO raise quickly approaches $3B

5 years ago

Wading deeper into target discovery and validation, Immunai bags $60M to beef up both AI algorithms and lab benches

5 years ago

With crossover round in its pocket, synthetic lethality-focused Cyteir Therapeutics eyes a jump onto Nasdaq

5 years ago

Versant spinout lands $80M to go 'much broader' than the old Roche partnership that birthed it

5 years ago

Sana gets a competitor as Takeda, 5AM pour $170M into a Fred Hutch pioneer's quest to unseat CAR-T, ex vivo gene therapy

5 years ago

Eli Casdin and Icahn protégé find a home for their $450M SPAC, merging with Sema4

5 years ago

On the hunt for a better antibody, BigHat Biosciences debuts with $19M Series A to scale its 'wet lab' AI platform

5 years ago

A year after FTC nixed Illumina buyout, SoftBank bets $900M on PacBio's new vision

5 years ago

'Industrializing the production of cells': Another iPSC player joins the quest for off-the-shelf cell therapies

5 years ago

With 'rapid' progress of pediatric brain cancer treatment, Day One sees broad excitement in new crossover round

5 years ago

Nautilus set to go public in reverse merger with Perceptive SPAC, aims to test proteomics platform with big-name backers

5 years ago

The SPAC attack has just begun. And the Richard Branson deal is just the tip of the biotech iceberg

5 years ago

A synthetic lethality player emerges in China, armed with lessons on undruggable oncogene from Nobel laureate's lab

5 years ago

IPO tracker: After another three pricings bring total raise close to $3B, debuts expected to slow in short week

5 years ago

Vor leads a new pack of IPOs to price, continuing steady stream of companies making leap to the Nasdaq

5 years ago

Richard Branson takes 23andMe public with his SPAC, as the GlaxoSmithKline partner aims to beef up drug R&D

5 years ago

Sana prices at near record IPO, leading pack of Nasdaq newcomers

5 years ago

Senior AbbVie liaison quits job to launch neuro startup, with sights set on ALS

5 years ago

First page Previous page 83 84 858687 88 89 Next page Last page